[go: up one dir, main page]

MX2022004678A - Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. - Google Patents

Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2022004678A
MX2022004678A MX2022004678A MX2022004678A MX2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A
Authority
MX
Mexico
Prior art keywords
disease
beta
treating alzheimer
amyloid antibody
antibody
Prior art date
Application number
MX2022004678A
Other languages
English (en)
Inventor
Thierry Bussiere
Roger Nitsch
Haeberlein Samantha Budd
Ying Tian
Laura Nisenbaum
Raj Rajagovindan
Gersham Dent
John Beaver
Edward Plowey
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2022004678A publication Critical patent/MX2022004678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos para tratar la enfermedad de Alzheimer en un sujeto humano que lo necesite que comprenden la administración de dosis múltiples de un anticuerpo anti-beta amiloide (por ejemplo, aducanumab) al sujeto.
MX2022004678A 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. MX2022004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2022004678A true MX2022004678A (es) 2022-08-15

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004678A MX2022004678A (es) 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US20220372123A1 (es)
EP (1) EP4048695A1 (es)
JP (2) JP2022553329A (es)
KR (1) KR20220084095A (es)
CN (1) CN114599393A (es)
AU (1) AU2020371612A1 (es)
BR (1) BR112022007595A2 (es)
CA (1) CA3158513A1 (es)
CO (1) CO2022004902A2 (es)
IL (1) IL292363A (es)
JO (1) JOP20220092A1 (es)
MX (1) MX2022004678A (es)
WO (1) WO2021081101A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
US20210122817A1 (en) 2018-01-31 2021-04-29 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
EP4426349A4 (en) * 2021-11-03 2025-10-29 Biogen Ma Inc METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE
EP4473009A1 (en) * 2022-02-02 2024-12-11 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
KR20250095673A (ko) * 2022-10-25 2025-06-26 기초과학연구원 뇌척수액 배액을 촉진하는 두개외 방법
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3239174A1 (en) 2007-01-05 2017-11-01 University of Zurich Anti-beta-amyloid antibody and uses thereof
EP2152309B1 (en) * 2007-05-14 2013-07-10 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MX341369B (es) * 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
SG11201400125RA (en) * 2011-09-19 2014-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
HK1215673A1 (zh) * 2012-12-07 2016-09-09 Biogen International Neuroscience Gmbh 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA3026598A1 (en) * 2016-06-07 2017-12-14 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease

Also Published As

Publication number Publication date
JOP20220092A1 (ar) 2023-01-30
CA3158513A1 (en) 2021-04-29
AU2020371612A1 (en) 2022-05-19
KR20220084095A (ko) 2022-06-21
IL292363A (en) 2022-06-01
US20220372123A1 (en) 2022-11-24
EP4048695A1 (en) 2022-08-31
JP2026012271A (ja) 2026-01-23
CO2022004902A2 (es) 2022-07-08
WO2021081101A1 (en) 2021-04-29
CN114599393A (zh) 2022-06-07
JP2022553329A (ja) 2022-12-22
BR112022007595A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
ECSP19075146A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
ZA202107358B (en) Method for treating alzheimer's disease
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
CL2021001389A1 (es) Formulaciones en cápsula
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR119159A1 (es) Tratamientos de angioedema
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.